{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:00:16Z","timestamp":1777694416430,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Case Rep"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:p>Generalized lipodystrophy (GL) is a rare inherited or acquired disease characterized by widespread loss of subcutaneous fat, leading to leptin deficiency, ectopic fat deposition, and severe metabolic abnormalities. Previous studies have shown the benefit of leptin replacement (metreleptin) in ameliorating metabolic complications, but little is known about the experience of metreleptin treatment outside of a research setting. We report on post-marketing clinical experience with metreleptin therapy in three patients with GL and marked hypoleptinemia, uncontrolled diabetes, and hypertriglyceridemia. After metreleptin treatment for 12\u2013168 weeks, the mean glycated hemoglobin decreased from 10.9% to 5.8%, and serum triglycerides were normalized (a mean decline of 90%). These benefits were observed within weeks of starting therapy, were durable, and were accompanied by subjective improvements in quality of life, decreased need for concomitant medications, and no significant adverse effects. Metreleptin was safe and effective in normalizing certain severe metabolic abnormalities in the clinic setting.<\/jats:p>","DOI":"10.4137\/ccrep.s40196","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T12:14:24Z","timestamp":1507810464000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Metreleptin Treatment in Three Patients with Generalized Lipodystrophy"],"prefix":"10.4137","volume":"9","author":[{"given":"Carla","family":"Musso","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Hospital Franc\u00e9s, Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Major","sequence":"additional","affiliation":[{"name":"Hospital Municipal Materno Infantil de San Isidro, Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Andres","sequence":"additional","affiliation":[{"name":"Hospital de Ni\u00f1os Pedro de Elizalde, Buenos Aires, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinaya","family":"Simha","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,1,5]]},"reference":[{"key":"bibr1-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.4158\/endp.19.1.v767575m65p5mr06"},{"key":"bibr2-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.5.8624"},{"key":"bibr3-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2004.08.021"},{"key":"bibr4-CCRep.S40196","volume-title":"MYALEPT (metreleptin): US prescribing information.","year":"2015"},{"key":"bibr5-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00290109"},{"key":"bibr6-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1502-9"},{"key":"bibr7-CCRep.S40196","unstructured":"BrownR.J., MuniyappaR., GharibA.M. Recombinant methionyl human leptin (metreleptin) improves glucose and lipid metabolism during constant food intake in humans [abstract 332-OR]. Presented at the 76th Scientific Sessions of the American Diabetes Association; June 10\u20134, 2016; New Orleans, LA."},{"key":"bibr8-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012437"},{"key":"bibr9-CCRep.S40196","unstructured":"DhankharP., IsupovT., Araujo-VilarD. Estimating quality of life for patients with lipodystrophy [abstract PSY7]. Presented at ISPOR 20th Annual International Meeting; May 16\u201320, 2015; Philadelphia, PA."},{"key":"bibr10-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.7.1994"},{"key":"bibr11-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20672"},{"key":"bibr12-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.007"},{"key":"bibr13-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1966"},{"key":"bibr14-CCRep.S40196","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032140"}],"container-title":["Clinical Medicine Insights: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/CCRep.S40196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4137\/CCRep.S40196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/CCRep.S40196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:15:07Z","timestamp":1777454107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4137\/CCRep.S40196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":14,"alternative-id":["10.4137\/CCRep.S40196"],"URL":"https:\/\/doi.org\/10.4137\/ccrep.s40196","relation":{},"ISSN":["1179-5476","1179-5476"],"issn-type":[{"value":"1179-5476","type":"print"},{"value":"1179-5476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"article-number":"CCRep.S40196"}}